EMA grants Orphan Drug Designation to GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 to treat pulmonary neuroendocrine carcinoma: London, UK Wednesday, October 29, 2025 ...
SMT’s Supraflex Cruz shows consistent and robust clinical outcomes: Our Bureau, Mumbai Wednesday, October 29, 2025, 16:15 Hrs [IST] Sahajanand Medical Technologies (SMT), a medi ...
Ajinomoto Bio-Pharma & Olon S.p.A. form strategic partnership to advance large-scale peptide and protein manufacturing: Tokyo, Japan Wednesday, October 29, 2025, 17:00 Hrs [IST] A ...
Orchestra BioMed enrols first patients in Virtue SAB pivotal investigational device exemption coronary trial: New Hope, Pennsylvania Wednesday, October 29, 2025, 18:00 Hrs [IST] O ...
GSK and Empirico ink license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases: London, UK Wednesday, October 29, 2025, 09:00 Hr ...
Merck & Eisai announce Welireg plus Lenvima meets primary endpoint of PFS in certain previously treated patients with advanced RCC: Rahway, New Jersey Wednesday, October 29, 2025, ...
D, a new standard in deuterated reagents for pharma innovation: Tewksbury, Massachusetts Wednesday, October 29, 2025, 12:00 Hrs [IST] Camb ...
Metropolis Healthcare study reveals 46% of tested individuals show vitamin D deficiency across India
Metropolis Healthcare study reveals 46% of tested individuals show vitamin D deficiency across India: Our Bureau, Bengaluru Wednesday, October 29, 2025, 14:30 Hrs [IST] Metropolis ...
Ramaiah Memorial Hospital underscores need for bone health & osteoporosis diagnosis through advanced DXA scanner: Our Bureau, Bengaluru Wednesday, October 29, 2025, 14:45 Hrs [IST ...
Philips introduces industry-first cath lab integration; paving the way for CT-guided PCI: San Francisco Wednesday, October 29, 2025, 14:00 Hrs [IST] Royal Philips, a global leader ...
Salesforce India debuts Agentforce Life Sciences to drive customer engagement and alleviate doctor burnout: Our Bureau, Bengaluru Wednesday, October 29, 2025, 16:30 Hrs [IST] Sale ...
Roche’s phase III INShore study of Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome meets its primary endpoints: Basel Wednesday, October 29, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results